US Bioservices is now dispensing Novartis’ KISQALI
March 16, 2017
The U.S Food and Drug Administration recently approved Novartis’ KISQALI (ribociclib) for the treatment of postmenopausal women with HR+/HER2- advanced or metastatic breast cancer.
.png?bc=ffffff&h=60&la=en&w=250&hash=D4E558BE41F5D9E7E7CC458758B16488B3D292F9){kind=logo}
The U.S Food and Drug Administration recently approved Novartis’ KISQALI (ribociclib) for the treatment of postmenopausal women with HR+/HER2- advanced or metastatic breast cancer.